This volume focuses on therapeutic targets that were identified after TNF blockade. All these targets have recently been registered or are currently under development for the treatment of rheumatoid arthritis. Each chapter explores the biological rationale of a distinct therapeutic target in great detail. Readers will discover the latest in vitro work, animal models, and results from clinical trials.
"synopsis" may belong to another edition of this title.
The volume focuses on therapeutic targets that were identified after TNF blockade and that have recently been registered or are currently under development for the treatment of rheumatoid arthritis. Each chapter discusses the biological rationale in great detail, including in vitro work and work in animal models, and where appropriate, results from clinical trials.
The book is written by an international authorship of experts in this field. It is of interest to rheumatologists, immunologists, internists, investigators in immunology and rheumatology as well as the pharmaceutical industry.
"About this title" may belong to another edition of this title.
Book Description Condition: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. Seller Inventory # ABEOCT23-196253
Book Description Condition: New. pp. xii + 225 1st Edition. Seller Inventory # 26463665
Book Description Condition: New. pp. xii + 225 Illus. Seller Inventory # 7384302
Book Description Condition: New. PRINT ON DEMAND Book; New; Fast Shipping from the UK. No. book. Seller Inventory # ria9783764382377_lsuk
Book Description Buch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This volume focuses on therapeutic targets that were identified after TNF blockade. All these targets have recently been registered or are currently under development for the treatment of rheumatoid arthritis. Each chapter explores the biological rationale of a distinct therapeutic target in great detail. Readers will discover the latest in vitro work, animal models, and results from clinical trials. 228 pp. Englisch. Seller Inventory # 9783764382377
Book Description Buch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - During the past decades important breakthroughs have been made in the treatment of rheumatoid arthritis (RA). First, the implementation of low-dose methotrexate and other conventional disease-modifying anti-rheumatic drugs was introduced as an effective treatment. Second, it was recognized that early immunomodu- tory treatment is crucial for controlling the disease and its long-term destructive effects more effectively. Parallel advances in research on the pathogenesis of RA and cytokine biology converged in identifying tumor necrosis factor (TNF) as a key factor in inflammation and matrix destruction. The concept arose that elevated TNF concentrations at the sites of inflammation were driving disease pathology, and the removal of excess TNF from sites of inflammation became a therapeutic goal. Clearly, TNF blockade has revolutionized the treatment of RA, as well as other immune-mediated inflammatory diseases. Anti-TNF treatment results in cli- cal benefit in a significant proportion of the patients, and it has provided proof of concept for the principle of targeted therapy. Despite the impressive disease-modifying effects of the TNF blockers, not all patients respond, and patients who exhibited an initial response may lose response due to the development of anti-drug antibodies (human anti-chimeric antibodies and human anti-human antibodies, respectively) and perhaps as a result of escape mechanisms related to the disease process. In fact, the majority of the patients still have disease activity in at least one or two actively inflamed joints. Seller Inventory # 9783764382377
Book Description Hardcover. Condition: new. This item is printed on demand. Seller Inventory # 9783764382377
Book Description Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Focuses on therapeutic targets that have recently been registered or are currently under development.Each chapter discusses the biological rationale in great detail including results from clinical trials.Written by an international aut. Seller Inventory # 5279800
Book Description Condition: New. Seller Inventory # ABLIING23Apr0316110059247